HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedersen, A. H. Articles by Hedner, U. Search for Related Content PubMed PubMed Citation Articles by Pedersen, A. H. Articles by Hedner, U. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 28, 16786-16793, 10, 1990

Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor- initiated coagulation reactions

AH Pedersen, O Nordfang, F Norris, FC Wiberg, PM Christensen, KB Moeller, J Meidahl-Pedersen, TC Beck, K Norris and U Hedner
Department of Pathology, University of New Mexico School of Medicine, Albuquerque 87131.

Previous studies have shown that extrinsic pathway inhibitor (EPI) is an effective inhibitor of factor Xa alone or factor VIIa-tissue factor complex in the presence of factor Xa. Since tissue factor exposure is implicated in thrombogenesis, we hypothesized that EPI may be valuable in the treatment of some thromboembolic episodes. Furthermore, EPI may be an important factor in bleeding complications in hemophiliacs. In the present study, human EPI was expressed in baby hamster kidney cells using a mammalian expression vector. Transfected cells expressed 1-2 micrograms/ml of recombinant EPI (rEPI) which was purified to homogeneity by heparin-Sepharose chromatography, ion-exchange chromatography, and reverse phase high performance liquid chromatography. Purified rEPI exhibited a specific activity of 30,000 units/mg and migrated as a single band in sodium dodecyl sulfate- polyacrylamide gel electrophoresis with an apparent molecular weight of 42,000. In addition, the NH2-terminal sequence of rEPI was identical to that of HepG2 EPI and HeLa EPI. The ability of rEPI to inhibit factor X activation by a complex of factor VIIa-tissue factor was then examined in the presence and absence of plasma concentrations of human factors VIII and IX. Using relipidated human brain tissue factor apoprotein, rEPI inhibited the factor VIIa-mediated activation of factor X half- maximally at 2.5 and 1 nM in the presence and absence of factors VIII and IX, respectively. Using monolayers of a human bladder carcinoma cell line (J82) as the source of tissue factor, the activation of factor X by cell-bound factor VIIa was inhibited half-maximally by 5 nM rEPI in the presence of factors VIII and IX. The proteolytic activity of J82 cell-bound factor Xa toward prothrombin was inhibited half- maximally at approximately 5 nM rEPI, while the amidolytic activity of factor Xa in solution was inhibited by rEPI with a Ki of 130 pM. Recombinant EPI also inhibited the amidolytic activity of factor VIIa half-maximally at 10 nM rEPI in the presence of relipidated tissue factor apoprotein and calcium. These results indicate that, in the presence of plasma concentrations of factors VIII and IX, at least 10 times the plasma concentration of EPI is required to reduce factor VIIa- dependent factor X activation one order of magnitude in vitro. In the absence of functional factor VIII and IX, rEPI at plasma levels was a potent inhibitor of factor VIIa-mediated factor X activation, and this activity presumably accounts for the inability of hemophiliacs to initiate hemostasis via the extrinsic pathway.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Persson, M. Kjalke, and O. H. Olsen Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity PNAS, October 31, 2001; (2001) 241339498. [Abstract] [Full Text] [PDF]

				C. B. Hansen, C. Pyke, L. C. Petersen, and L. V. M. Rao Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor Blood, March 15, 2001; 97(6): 1712 - 1720. [Abstract] [Full Text] [PDF]

				M. Kjalke, A. Silveira, A. Hamsten, U. Hedner, and M. Ezban Plasma Lipoproteins Enhance Tissue Factor-Independent Factor VII Activation Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1835 - 1841. [Abstract] [Full Text] [PDF]

				C. B. Hansen, B. van Deurs, L. C. Petersen, and L. V. M. Rao Discordant Expression of Tissue Factor and Its Activity in Polarized Epithelial Cells. Asymmetry in Anionic Phospholipid Availability as a Possible Explanation Blood, September 1, 1999; 94(5): 1657 - 1664. [Abstract] [Full Text] [PDF]

				T.-C. Wun and M. O. Palmier Heparin-tissue Factor Pathway Inhibitor Complexes: Anticoagulant and Pharmacokinetic Properties Clinical and Applied Thrombosis/Hemostasis, July 1, 1998; 4(3): 179 - 188. [Abstract] [PDF]

				R. J. Baugh, G. J. Broze Jr., and S. Krishnaswamy Regulation of Extrinsic Pathway Factor Xa Formation by Tissue Factor Pathway Inhibitor J. Biol. Chem., February 20, 1998; 273(8): 4378 - 4386. [Abstract] [Full Text] [PDF]

				M. Iino, D. C. Foster, and W. Kisiel Quantification and Characterization of Human Endothelial Cell–Derived Tissue Factor Pathway Inhibitor-2 Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 40 - 46. [Abstract] [Full Text] [PDF]

				S. Higashi, N. Matsumoto, and S. Iwanaga Conformation of Factor VIIa Stabilized by a Labile Disulfide Bond (Cys-310-Cys-329) in the Protease Domain Is Essential for Interaction with Tissue Factor J. Biol. Chem., October 10, 1997; 272(41): 25724 - 25730. [Abstract] [Full Text] [PDF]

				D. Bharadwaj, M. Iino, M. Kontoyianni, K. J. Smith, D. C. Foster, and W. Kisiel Factor VII Central. A NOVEL MUTATION IN THE CATALYTIC DOMAIN THAT REDUCES TISSUE FACTOR BINDING, IMPAIRS ACTIVATION BY FACTOR XA, AND ABOLISHES AMIDOLYTIC AND COAGULANT ACTIVITY J. Biol. Chem., November 29, 1996; 271(48): 30685 - 30691. [Abstract] [Full Text] [PDF]

				S. Higashi, N. Matsumoto, and S. Iwanaga Molecular Mechanism of Tissue Factor-mediated Acceleration of Factor VIIa Activity J. Biol. Chem., October 25, 1996; 271(43): 26569 - 26574. [Abstract] [Full Text] [PDF]

				E. Persson, H. Bak, and O. H. Olsen Substitution of Valine for Leucine 305 in Factor VIIa Increases the Intrinsic Enzymatic Activity J. Biol. Chem., July 27, 2001; 276(31): 29195 - 29199. [Abstract] [Full Text] [PDF]

				E. Persson, M. Kjalke, and O. H. Olsen Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity PNAS, November 20, 2001; 98(24): 13583 - 13588. [Abstract] [Full Text] [PDF]